Litcius/Paper detail

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

Shintaro Takaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Hironori Ochi, Hiroyuki Marusawa, Shinichiro Nakamura, Toshifumi Tada, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Atsunori Kusakabe, Koichiro Furuta, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Takashi Tamada, Chitomi Hasebe, Chikara Ogawa, Takashi Sato, Nobuharu Tamaki, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi

2023Investigational New Drugs19 citationsDOI

Topics & Concepts

MedicineInternal medicineHazard ratioAtezolizumabBevacizumabHepatocellular carcinomaGastroenterologyConfidence intervalAdverse effectProteinuriaCohortBilirubinRetrospective cohort studyCancerChemotherapyNivolumabKidneyImmunotherapyHepatocellular Carcinoma Treatment and PrognosisHepatitis C virus researchHepatitis B Virus Studies
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group | Litcius